Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemagglutinin (HA) is a surface glycoprotein of the influenza A virus, functioning as both the receptor-binding and membrane fusion protein essential for viral entry into host cells. The H7 subtype refers to one of the antigenic variants within the hemagglutinin family, commonly associated with avian influenza strains but also capable of infecting humans. It binds sialic acid-containing receptors on target cell surfaces via its globular head domain, facilitating initial virus attachment. After endocytosis into host cells and exposure to acidic pH within endosomes, conformational changes trigger fusion between viral and cellular membranes allowing genome release into cytoplasm. Hemagglutinin is a principal target for neutralizing antibodies generated during infection or vaccination.
Inhibition of viral entry by blocking receptor binding or membrane fusion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemagglutinin protein (H7 subtype) (HA (H7)).